Noticias y Eventos

Descubra las novedades en el campo de las patologías oculares hereditarias

Blog operado por el equipo de DBGen que actualiza terapias, noticias y eventos relacionados con las enfermedades hereditarias oculares. Le invitamos a participar en este foro.

Filters

Category list

Leber Congenital Amaurosis DBGen Macular degeneration Age-related macular degeneration Genetic Diagnosis Retinal Dystrophy Gene editing Research Mutation Patients Retinitis pigmentosa Stargardt Therapy Cell Therapy Gene Therapy

Entry date

July 2020 (1)

May 2020 (2)

April 2020 (1)

March 2020 (1)

February 2020 (1)

January 2020 (1)

December 2019 (2)

November 2019 (1)

October 2019 (2)

September 2019 (1)

August 2019 (2)

July 2019 (1)

June 2019 (2)

May 2019 (1)

April 2019 (2)

March 2019 (2)

February 2019 (1)

January 2019 (1)

December 2018 (2)

October 2018 (2)

September 2018 (1)

July 2018 (2)

May 2018 (2)

April 2018 (3)

March 2018 (2)

February 2018 (3)

January 2018 (2)

December 2017 (1)

Subscribe to our blog

Advances in gene therapy for retinitis pigmentosa due to RPGR gene mutation

12/05/20 - Retinal Dystrophy, Retinitis pigmentosa, Gene Therapy,

In the first months of 2020, positive results in gene therapy of X-linked retinitis pigmentosa (XLRP) have been reported. XLRP is an inherited genetic disorder that causes progressive vision loss, mainly in men. It begins in childhood with night blindness, progresses with the gradual reduction of the visual field and visual acuity, and leads to blindness in the fourth decade...

A third of the world’s population carries mutations associated with retinal dystrophies

06/04/20 - Genetic Diagnosis, Retinal Dystrophy, Research, Mutation,

A very recent study published in the scientific journal PNAS highlights an estimate, on a global scale, of the frequency of individuals carrying pathogenic mutations responsible for inherited retinal dystrophies (IRD) and illustrates the prevalence of this group of diseases. These data are highly relevant for genetic diagnosis, genetic counselling and the design of new therapies. The authors studied the...

First gene therapy application of Luxturna in the UK

26/02/20 - Leber Congenital Amaurosis, Retinal Dystrophy, Therapy, Gene Therapy,

This February Moorfields Eye Hospital in London and Radcliffe Hospital in Oxford have started treating patients affected by Leber congenital amaurosis (LCA) with the Luxturna gene therapy. LCA is a childhood-onset severe retinal dystrophy, which causes irreversible blindness for which, until now, no treatment was available. Luxturna (voretigene neparvovec) is also the first gene therapy approved for the treatment of an...

Gene therapies open very promising scenarios for the treatment of genetic blindness

23/09/19 - Retinal Dystrophy, Gene Therapy,

Not so far ago, a patient that was clinically diagnosed with a retinal inherited dystrophy had to face an unavoidable outcome, eventual blindness. No effective treatment to cure or halt the progression of the disease was available. This gloomy perspective has been completely upturned by the implementation of cutting edge technologies, and the future looks promising for patients and their...

New RNA therapy for autosomal dominant retinitis pigmentosa

27/08/19 - Retinal Dystrophy, Gene Therapy,

The United States Food and Drug Administration (FDA) has just approved the designation of the QR-1123 therapy by the Dutch company ProQR as a new investigational drug. This drug aims to treat a form of autosomal dominant retinitis pigmentosa (RPad) caused by the P23H mutation in the rhodopsin gene (RHO). QR-1123 is an antisense oligonucleotide, that is, a short RNA...

A race against the clock for Leber congenital amaurosis gene therapy

14/08/19 - Leber Congenital Amaurosis, Retinal Dystrophy, Gene Therapy,

ProQR Sepofarsen therapy On July 29, the Dutch company ProQR announced that the European Medicines Agency (EMA) has granted access to the Agency's priority medicine program (PRIME) to its Sepofarsen therapy (QR-110), designed for the treatment of Leber congenital amaurosis (LCA10), a childhood blinding disorder, caused by the c.2991+1655A>G (p.Cys998 *) mutation in the CEP290 gene. The EMA PRIME program...

1 2 3 >